IP Library Granted Patent US 7,569,597
Granted Patent B2
US 7,569,597 · App. 12/070,322 · Granted Aug 4, 2009

Isoindoline compounds and methods of their use

Assignee: Celgene Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,569,597
App. No.
12/070,322
Granted
Aug 4, 2009
Kind
B2
Abstract

Novel isoindoline compounds are disclosed. Methods of treating, preventing and/or managing cancer, diseases and disorders associated with, or characterized by, undesired angiogenesis, and diseases and disorders mediated by PDE 4, using the compounds are also disclosed.

Claims (2)

1. A method of treating a disease or disorder mediated by PDE 4, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of the formula:

or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof, wherein the disease or disorder mediated by PDE 4 is asthma, chronic obstructive pulmonary disease, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, or Crohn's disease.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2019
From: CELGENE CORPORATION
To: AMGEN INC.
Reel/Frame 051181/0038 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2008
From: MULLER, GEORGE W.; MAN, HON WAH
To: CELGENE CORPORATION
Reel/Frame 020583/0996 →
Continuity (2)
Division 1090033200 · Jul 28, 2004
Related Publication 20080145336A1 · Jun 19, 2008